These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 18436089)

  • 1. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session.
    Brunet P; Simon N; Opris A; Faure V; Lorec-Penet AM; Portugal H; Dussol B; Berland Y
    Am J Kidney Dis; 2008 May; 51(5):789-95. PubMed ID: 18436089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.
    Klingel R; Schwarting A; Lotz J; Eckert M; Hohmann V; Hafner G
    Kidney Blood Press Res; 2004; 27(4):211-7. PubMed ID: 15273423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of coagulation and anti-Xa factor when using a heparin-coated AN69ST® dialyser.
    Sánchez-Canel JJ; Pons-Prades R; Salvetti ML; Seores A; Vázquez M; Pérez-Alba A; Tamarit E; Calvo-Gordo C; Villatoro J
    Nefrologia; 2012; 32(5):605-12. PubMed ID: 23013946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
    Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
    Lavaud S; Canivet E; Wuillai A; Maheut H; Randoux C; Bonnet JM; Renaux JL; Chanard J
    Nephrol Dial Transplant; 2003 Oct; 18(10):2097-104. PubMed ID: 13679486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].
    Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J
    Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin elimination and hemostasis in hemodialysis.
    Wilhelmsson S; Lins LE
    Clin Nephrol; 1984 Dec; 22(6):303-6. PubMed ID: 6525772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated hepatocyte growth factor levels at the beginning of high-flux hemodialysis are due to heparin administration.
    Christidou F; Bamichas G; Galaktidou G; Fragidis S; Gionanlis L; Frangia T; Bischiniotis T; Sombolos K
    Ren Fail; 2008; 30(9):861-4. PubMed ID: 18925524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of fragmin in program hemodialysis of patients with terminal chronic renal failure].
    Kozlova TV; Shilo VIu; Denisov AIu
    Klin Med (Mosk); 2005; 83(9):45-9. PubMed ID: 16279040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of heparin anticoagulation for hemodialysis.
    Davenport A
    Hemodial Int; 2011 Oct; 15 Suppl 1():S43-8. PubMed ID: 22093600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients.
    Perry SL; O'Shea SI; Byrne S; Szczech LA; Ortel TL
    Thromb Haemost; 2006 Dec; 96(6):750-5. PubMed ID: 17139369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin.
    Anastassiades E; Lane DA; Ireland H; Flynn A; Curtis JR
    Clin Nephrol; 1989 Dec; 32(6):290-6. PubMed ID: 2558829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin-grafted dialysis membrane allows minimal systemic anticoagulation in regular hemodialysis patients: a prospective proof-of-concept study.
    Kessler M; Gangemi C; Gutierrez Martones A; Lacombe JL; Krier-Coudert MJ; Galland R; Kielstein JT; Moureau F; Loughraieb N
    Hemodial Int; 2013 Apr; 17(2):282-93. PubMed ID: 22925178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session: the impact of the administered dose.
    Fourtounas C
    Am J Kidney Dis; 2008 Oct; 52(4):805-6; author reply 806-7. PubMed ID: 18805352
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study).
    Imberti D; Legnani C; Baldini E; Cini M; Nicolini A; Guerra M; De Paoli M; Zanardi A; Palareti G
    Thromb Res; 2009 Dec; 124(6):667-71. PubMed ID: 19482341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
    Kruse MW; Lee JJ
    Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of r-hirudin vs. heparin on blood-membrane interactions during hemodialysis.
    van Wyk V; Badenhorst PN; Kotzé HF
    Clin Nephrol; 1997 Dec; 48(6):381-7. PubMed ID: 9438098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J; Johnston N; Siegbahn A
    Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
    Boneu B; Navarro C; Cambus JP; Caplain H; d'Azemar P; Necciari J; Duret JP; Gaud C; Sié P
    Thromb Haemost; 1998 Feb; 79(2):338-41. PubMed ID: 9493587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.